A contemporary evidence basis for neoadjuvant chemotherapy in upfront resectable pancreatic adenocarcinoma: a systematic review of the literature
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival. Local
control through surgical resection paired with radiotherapy and chemotherapy comprise the …
control through surgical resection paired with radiotherapy and chemotherapy comprise the …
Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. Pooled data from 3 randomized controlled trials
Objective: The aim of this study was to pool data from randomized controlled trials (RCT)
limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a …
limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a …
Neoadjuvant and adjuvant chemotherapy in pancreatic cancer
U Klaiber, CS Leonhardt, O Strobel, C Tjaden… - … archives of surgery, 2018 - Springer
Abstract Background Only 15–20% of patients with pancreatic ductal adenocarcinoma
(PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment …
(PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment …
Neoadjuvant treatment in resectable pancreatic cancer. Is it time for pushing on it?
M Vivarelli, F Mocchegiani, D Nicolini, A Vecchi… - Frontiers in …, 2022 - frontiersin.org
Pancreatic resection still represents the only curative option for patients affected by
pancreatic ductal adenocarcinoma (PDAC). However, the association with modern …
pancreatic ductal adenocarcinoma (PDAC). However, the association with modern …
A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma
The aim of this study was to evaluate outcomes of patients with resectable pancreatic
adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and …
adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and …
Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence
At the time of diagnosis, only about 20% of patients with pancreatic ductal adenocarcinoma
(PDAC) have resectable disease. PDAC treatment necessitates a multidisciplinary …
(PDAC) have resectable disease. PDAC treatment necessitates a multidisciplinary …
Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis
K Rangarajan, PH Pucher… - The Annals of The …, 2019 - publishing.rcseng.ac.uk
Background Pancreatic ductal adenocarcinoma remains a disease with a poor prognosis
despite advances in surgery and systemic therapies. Neoadjuvant therapy strategies are a …
despite advances in surgery and systemic therapies. Neoadjuvant therapy strategies are a …
Neoadjuvant chemotherapy and disease recurrence after curative-intent surgery in patients with pancreatic adenocarcinoma: A single-center retrospective review.
e18610 Background: Early stage pancreatic ductal adenocarcinoma (PDAC) account for up
to 30% of newly diagnosed patients. Until recently, the mainstay of treatment remained …
to 30% of newly diagnosed patients. Until recently, the mainstay of treatment remained …
Neoadjuvant treatments for pancreatic ductal adenocarcinoma: where we are and where we are going
A Coppola, T Farolfi, V La Vaccara, I Iannone… - Journal of Clinical …, 2023 - mdpi.com
Background: Pancreatic ductal adenocarcinoma (PDAC) represents a challenging disease
for the surgeon, oncologist, and radiation oncologist in both diagnostic and therapeutic …
for the surgeon, oncologist, and radiation oncologist in both diagnostic and therapeutic …
Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials
The efficacy of neoadjuvant therapy (NT) versus surgery first (SF) for pancreatic ductal
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …